Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Pipeline Review, H2 2016', provides in depth analysis on Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information on the Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - The report reviews Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) Overview 9 Therapeutics Development 10 Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Products under Development by Stage of Development 10 Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Products under Development by Therapy Area 11 Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Products under Development by Indication 12 Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Pipeline Products Glance 14 Late Stage Products 14 Early Stage Products 15 Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Products under Development by Companies 16 Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Products under Development by Universities/Institutes 20 Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Therapeutics Assessment 22 Assessment by Monotherapy/Combination Products 22 Assessment by Mechanism of Action 23 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Companies Involved in Therapeutics Development 27 AbbVie Inc 27 Advenchen Laboratories LLC 28 Aeterna Zentaris Inc 29 Amgen Inc 30 Astex Pharmaceuticals Inc 31 AstraZeneca Plc 32 Chipscreen Biosciences Ltd 33 Cielo Therapeutics Inc 34 Merck KGaA 35 Nemucore Medical Innovations Inc 36 Sanofi 37 Sareum Holdings Plc 38 Vertex Pharmaceuticals Inc 39 Vichem Chemie Research Ltd 40 Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Drug Profiles 41 AL-8326 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 AMG-900 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 AT-9283 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 AZD-2811 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 CS-2164 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 danusertib - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 ilorasertib - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 NMI-900 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 SAR-156497 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 SAR-3 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 SAR-4 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Small Molecule to Inhibit Aurora B Kinase for Pancreatic Cancer - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Small Molecules to Inhibit Aurora A/B Kinase for Oncology - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Small Molecules to Inhibit Aurora B Kinase for Oncology - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Small Molecules to Inhibit ERK2 and Aurora B Kinase for Oncology - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 VE-465 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Dormant Projects 63 Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Discontinued Products 70 Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Featured News & Press Releases 72 Aug 03, 2016: China and Hong Kong Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors 72 May 10, 2016: Data Published in Journal of Controlled Release Demonstrate Flexibility of ACCURINS to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and Tunable Release Kinetics 72 Feb 10, 2016: AZD2811 ACCURINS Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies 73 Nov 18, 2015: BIND Therapeutics Announces Initiation of Clinical Studies with Accurin AZD2811 in Solid Tumors 74 Sep 15, 2015: US and European Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors 75 Jun 23, 2015: BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca's Aurora B Kinase Inhibitor Accurin AZD2811 76 Apr 22, 2015: BIND Therapeutics Presents Data Highlighting Ability of Accurin drug candidate AZD2811 to Accumulate in Target Tissue at AACR Annual Meeting 2015 77 Mar 18, 2015: Data from Abstracts Validating Potential of BIND Therapeutics AZD2811 to be Presented at American Association for Cancer Research Annual Meeting 78 Mar 05, 2014: BIND Therapeutics to Present Data on Barasertib at the AACR 2014 Annual Meeting 79 Jul 15, 2013: Preclinical Development Candidate Selected for Aurora+FLT3 Inhibitor Programme 79 Sep 03, 2012: Chipscreen filed a new IND application on a novel dual-pathway targeted inhibitor Chiauranib to SFDA 79 May 16, 2012: Astex Pharmaceuticals To Present Data On AT9283 At ASCO Annual Meeting 80 Jan 27, 2012: Cancer Research UK Launches Trial Of New Drug To Treat Acute Childhood Leukemia 80 Dec 01, 2010: Astex to Present Encouraging Data on AT9283 in Combination with Docetaxel for Treatment of Non-Hodgkin's Lymphoma 81 Dec 01, 2010: Astex To Present Encouraging Data On AT9283 In Combination With Lenalidomide For Treatment Of Multiple Myeloma At ASH Annual Meeting 81 Appendix 82 Methodology 82 Coverage 82 Secondary Research 82 Primary Research 82 Expert Panel Validation 82 Contact Us 82 Disclaimer 83
List of Tables
Number of Products under Development for, H2 2016 10 Number of Products under Development by Therapy Area, H2 2016 11 Number of Products under Development by Indication, H2 2016 13 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Early Stage Products, H2 2016 15 Number of Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 (Contd..1) 18 Products under Development by Companies, H2 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2016 20 Products under Investigation by Universities/Institutes, H2 2016 21 Assessment by Monotherapy/Combination Products, H2 2016 22 Number of Products by Stage and Mechanism of Action, H2 2016 23 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 26 Pipeline by AbbVie Inc, H2 2016 27 Pipeline by Advenchen Laboratories LLC, H2 2016 28 Pipeline by Aeterna Zentaris Inc, H2 2016 29 Pipeline by Amgen Inc, H2 2016 30 Pipeline by Astex Pharmaceuticals Inc, H2 2016 31 Pipeline by AstraZeneca Plc, H2 2016 32 Pipeline by Chipscreen Biosciences Ltd, H2 2016 33 Pipeline by Cielo Therapeutics Inc, H2 2016 34 Pipeline by Merck KGaA, H2 2016 35 Pipeline by Nemucore Medical Innovations Inc, H2 2016 36 Pipeline by Sanofi, H2 2016 37 Pipeline by Sareum Holdings Plc, H2 2016 38 Pipeline by Vertex Pharmaceuticals Inc, H2 2016 39 Pipeline by Vichem Chemie Research Ltd, H2 2016 40 Dormant Projects, H2 2016 63 Dormant Projects (Contd..1), H2 2016 64 Dormant Projects (Contd..2), H2 2016 65 Dormant Projects (Contd..3), H2 2016 66 Dormant Projects (Contd..4), H2 2016 67 Dormant Projects (Contd..5), H2 2016 68 Dormant Projects (Contd..6), H2 2016 69 Discontinued Products, H2 2016 70 Discontinued Products (Contd..1), H2 2016 71
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
